Defendant
1 case as defendant.
LumiraDx UK Ltd. is a UK-based company that develops and commercializes point-of-care diagnostic platforms. Founded in 2014, the company is headquartered in London, United Kingdom. LumiraDx UK Ltd. operates as a subsidiary of LumiraDx Limited. In January 2024, Roche acquired LumiraDx's point-of-care diagnostics platform business. At the time of acquisition, LumiraDx had approximately 1,210 employees.
The company's primary offerings include a next-generation diagnostic platform that integrates various technologies and sample types into a single portable instrument. This platform delivers lab-comparable results in minutes for a range of conditions, including infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. LumiraDx also developed and commercialized COVID-19 testing solutions. Their diagnostic testing solutions are utilized globally in diverse healthcare settings such as laboratories, urgent care centers, physician offices, pharmacies, and schools.
LumiraDx UK Ltd. has appeared as a defendant in one tracked case, "Unified Patents v. Lumiradx UK Ltd.," before the Patent Trial and Appeal Board (PTAB). This indicates a posture of defending against patent challenges rather than actively asserting patents as a plaintiff.
An Inter Partes Review (IPR) was initiated by Unified Patents against patent owner Lumiradx UK Ltd. concerning patent 8630699, which concluded with a procedural termination.